Inovio Pharmaceuticals(US:INO) Globenewswire·2026-02-20 03:28Core Viewpoint - Rosen Law Firm is reminding investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, of the April 7, 2026, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Inovio securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5] - The deadline to move the Court to serve as lead plaintiff is April 7, 2026, with the lead plaintiff acting on behalf of other class members [2] Group 2: Law Firm Credentials - Rosen Law Firm specializes in securities class actions and has a strong track record, including the largest securities class action settlement against a Chinese company [3] - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [3] - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [3] Group 3: Case Background - Inovio Pharmaceuticals is a biotechnology company focused on DNA medicines for diseases like human papillomavirus (HPV) [4] - The lawsuit alleges that Inovio made false or misleading statements regarding the manufacturing of its CELLECTRA device and the prospects of its INO-3107 Biologics License Application (BLA) to the FDA [4] - It is claimed that the company overstated the regulatory and commercial prospects of INO-3107, leading to investor damages when the true information became public [4]